Evidence map›Paper›PMID 29785074›Full record

ReviewWorld journal of gastroenterology2018

Challenges in diagnosis of pancreatic cancer.

Lulu Zhang, Santosh Sanagapalli, Alina Stoita

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05172310 (PET Imaging of Tumors in Pancreas, Bile Ducts, Stomach and Ovaries by a Novel Tracer, 68Ga-FAPI-46 = Fibroblast Activation Protein Inhibitor), which is not on this map. Cited by 319 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
319citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05172310 phase1recruitingnot on this mapstarted 2021, after this paper: background citation

PET Imaging of Tumors in Pancreas, Bile Ducts, Stomach and Ovaries by a Novel Tracer, 68Ga-FAPI-46 = Fibroblast Activation Protein Inhibitor

TypeinterventionalSponsorKarolinska University HospitalRan2021 to 2029Enrolled410ConditionsPancreatic Neoplasms, Stomach Neoplasms, Bile Duct Neoplasms, Epithelial Ovarian CancerArms68Ga-FAPI-46, PET/CT
3 · Its place in the literature

Who cites it

319 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Artificial Intelligence in Pancreatic Imaging: A Systematic Review.United European gastroenterology journal · 2025
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Diets, Dietary Patterns, Single Foods and Pancreatic Cancer Risk: An Umbrella Review of Meta-Analyses.International journal of environmental research and public health · 2022
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Cancer imaging : the official publication of the International Cancer Imaging Society · 2025
    Trial
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

259 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lulu ZhangDepartment of Gastroenterology, St. Vincent's Hospital Sydney, Darlinghurst 2010, NSW, Australia.
Santosh SanagapalliDepartment of Gastroenterology, St. Vincent's Hospital Sydney, Darlinghurst 2010, NSW, Australia.
Alina StoitaDepartment of Gastroenterology, St. Vincent's Hospital Sydney, Darlinghurst 2010, NSW, Australia. astoita@stvincents.com.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is a growing source of cancer related death, yet has poor survival rates which have not improved in the last few decades. Its high mortality rate is attributed to pancreatic cancer biology, difficulty in early diagnosis and the lack of standardised international guidelines in assessing suspicious pancreatic masses. This review aims to provide an update in the current state of play in pancreatic cancer diagnosis and to evaluate the benefits and limitations of available diagnostic technology. The main modalities discussed are imaging with computed tomography, magnetic resonance imaging, endoscopic ultrasound and positron emission tomography and tissue acquisition with fine needle aspiration. We also review the improvements in the techniques used for tissue acquisition and the opportunity for personalised cancer medicine. Screening of high risk individuals, promising biomarkers and common mimickers of pancreatic cancer are also explored, as well as suggestions for future research directions to allow for earlier detection of pancreatic cancer. Timely and accurate diagnosis of pancreatic cancer can lead to improvements in the current poor outcome of this disease.

Indexed as

Biomarkers, TumorEarly Detection of CancerEndoscopic Ultrasound-Guided Fine Needle AspirationEndosonographyHumansMagnetic Resonance ImagingPancreasPancreatic NeoplasmsPositron-Emission TomographySurvival RateTomography, X-Ray ComputedBiomarkers, TumorBiomarkersChallengesDiagnosisEndoscopic ultrasoundImagingPancreatic cancerPitfallsScreening

Identifiers

PMID29785074
PMCPMC5960811

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.